Finland has, as the last Nordic country, decided to temporarily suspend AstraZeneca’s COVID-19 vaccine.
The country’s public health authority said two people developed blood clots after being vaccinated. As a result, vaccination will be suspended “until there is more information and a possible causality can be assessed”.
The Nordic countries are now reviewing the EMA verdict that the vaccine’s benefits outweigh its risks.
Pfizer and BioNTech have announced that the Medicines & Healthcare Products Regulatory Agency (MHRA) in the UK has granted a temporary authorization for emergency use for their mRNA vaccine (BNT162b2), against COVID-19. This constitutes the first Emergency Use Authorization following a worldwide Phase 3 trial of a vaccine to help…
BIO-Europe Spring 2020 is delivered digitally March 23-27 and the week will be filled with virtual partnering meetings, online company presentations, pre-recorded panels and a virtual exhibit. As a response to the new coronavirus (COVID-19) outbreak the organizers of BIO-Europe Spring, EBD Group, took the decision to instead of hosting…
Interim results from the ongoing Phase II/III COV002 trial of AZD1222 in the UK, led by the University of Oxford, demonstrated lower local and systemic reactions in older adults (≥56-69 years and ≥70 years) than younger adults (≥18-55 years) and generated similar robust immune responses against the SARS-CoV-2 virus across…
Nine leading US and European vaccine developers have signed a pledge to continue to make the safety and well-being of vaccinated individuals the top priority in development of the first COVID-19 vaccines. The CEOs of AstraZeneca, BioNTech, GlaxoSmithKline, Johnson & Johnson, Merck (known as MSD outside the United States and…
